NCT01976663 - A Safety and Effectiveness Study of JUVÉDERM VOLIFT® XC Versus Control for Moderate to Severe Nasolabial Folds | Biotech Hunter

Enrollment

126

Participants

Timeline

Start Date

October 29, 2013

Primary Completion Date

March 17, 2015

Study Completion Date

October 26, 2015

Conditions

Moderate to Severe Nasolabial Folds

Interventions

DEVICE

JUVEDERM VOLIFT® XC

Up to 4 mLs JUVEDERM VOLIFT® XC injected intradermally in one NLF (total; including initial and touch-up treatments) and up to 4 mLs JUVEDERM VOLIFT XC is allowed for repeat treatment. For asymmetric correction, only the more severe NLF is eligible for asymmetric correction.

DEVICE

Control

Up to 4 mLs Control injected intradermally in opposite NLF (total; including initial and touch-up treatments). Up to 4 mLs JUVEDERM VOLIFT XC is allowed for asymmetry correction and up to 4 mLs JUVEDERM VOLIFT XC is allowed for repeat treatment. Only the more severe NLF is eligible for asymmetric correction.

Trial Locations (7)

33146

Dermatology Research Institute, LLC, Coral Gables

Skin Research Institute, Coral Gables

33401

West Palm Beach

35205

Total Skin and Beauty Dermatology Center P.C., Birmingham

60611

Chicago

90036

Vitiligo and Pigmentation Institute of Southern California, Los Angeles

94115

San Francisco